Molecular Landscape and Therapeutic Strategies Against Colorectal Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Apr 27

PMID 38672633

Authors

Aakash Patel

Pat Gulhati

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide. Although the overall incidence of CRC is decreasing, the incidence of young-onset CRC, characterized by a diagnosis of CRC before age 50, is increasing. Outcomes for CRC patients are improving, partly due to comprehensive molecular characterization of tumors and novel therapeutic strategies. Advances in genomic and transcriptomic analyses using blood- and tumor-tissue-based sequencing have facilitated identification of distinct tumor subtypes harboring unique biological characteristics and therapeutic vulnerabilities. These insights have led to the development and incorporation of targeted therapies and immunotherapy in CRC treatment. In this review, we discuss the molecular landscape and key oncogenes/tumor suppressors contributing to CRC tumorigenesis, metastasis, and therapeutic resistance. We also discuss personalized therapeutic strategies for subsets of CRC patients and provide an overview of evolving novel treatments being evaluated in clinical trials.

Citing Articles

Colorectal Cancer: A Brief and Simplified Analysis of a Complex Disease.

Petrov K, Ivanov I, Popovska S, Betova T, Kamburova Z Medicina (Kaunas). 2025; 60(12.

PMID: 39768914 PMC: 11727892. DOI: 10.3390/medicina60122034.

Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.

Tardito S, Matis S, Zocchi M, Benelli R, Poggi A Int J Mol Sci. 2024; 25(13).

PMID: 39000238 PMC: 11241078. DOI: 10.3390/ijms25137131.

References

Wang H, Li Z, Ou Q, Wu X, Nagasaka M, Shao Y . NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer Med. 2022; 11(13):2541-2549. PMC: 9249987. DOI: 10.1002/cam4.4561. View

Sinicrope F . Lynch Syndrome-Associated Colorectal Cancer. N Engl J Med. 2018; 379(8):764-773. DOI: 10.1056/NEJMcp1714533. View

Pietrantonio F, Di Nicolantonio F, Schrock A, Lee J, Morano F, Fuca G . RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol. 2018; 29(6):1394-1401. DOI: 10.1093/annonc/mdy090. View

Holch J, Ricard I, Stintzing S, Modest D, Heinemann V . The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer. 2016; 70:87-98. DOI: 10.1016/j.ejca.2016.10.007. View

Venderbosch S, Nagtegaal I, Maughan T, Smith C, Cheadle J, Fisher D . Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014; 20(20):5322-30. PMC: 4201568. DOI: 10.1158/1078-0432.CCR-14-0332. View

Nagasaka M, Brazel D, Baca Y, Xiu J, Al-Hallak M, Kim C . Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset. Transl Oncol. 2023; 36:101744. PMC: 10410168. DOI: 10.1016/j.tranon.2023.101744. View

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

Hua H, He W, Chen N, He Y, Wu G, Ye F . Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy. Front Immunol. 2023; 13:974793. PMC: 9870311. DOI: 10.3389/fimmu.2022.974793. View

Koopman M, Kortman G, Mekenkamp L, Ligtenberg M, Hoogerbrugge N, Antonini N . Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009; 100(2):266-73. PMC: 2634718. DOI: 10.1038/sj.bjc.6604867. View

10.

Jin Z, Sinicrope F . Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. J Clin Oncol. 2022; 40(24):2735-2750. PMC: 9390830. DOI: 10.1200/JCO.21.02691. View

11.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

12.

Parikh A, Van Seventer E, Siravegna G, Hartwig A, Jaimovich A, He Y . Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021; 27(20):5586-5594. PMC: 8530842. DOI: 10.1158/1078-0432.CCR-21-0410. View

13.

Fakih M, Kopetz S, Kuboki Y, Kim T, Munster P, Krauss J . Sotorasib for previously treated colorectal cancers with KRAS mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2021; 23(1):115-124. DOI: 10.1016/S1470-2045(21)00605-7. View

14.

Ahcene Djaballah S, Daniel F, Milani A, Ricagno G, Lonardi S . HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. Am Soc Clin Oncol Educ Book. 2022; 42:1-14. DOI: 10.1200/EDBK_351354. View

15.

Karapetis C, Khambata-Ford S, Jonker D, OCallaghan C, Tu D, Tebbutt N . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-65. DOI: 10.1056/NEJMoa0804385. View

16.

Ratti M, Grizzi G, Passalacqua R, Lampis A, Cereatti F, Grassia R . NTRK fusions in colorectal cancer: clinical meaning and future perspective. Expert Opin Ther Targets. 2021; 25(8):677-683. DOI: 10.1080/14728222.2021.1978070. View

17.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

18.

Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona M . Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol. 2019; 139:53-66. DOI: 10.1016/j.critrevonc.2019.05.001. View

19.

Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T . Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021; 39(4):273-284. PMC: 8078423. DOI: 10.1200/JCO.20.02088. View

20.

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View